Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Alaska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Alaska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Alaska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Ellen Chirichella (NPI 1952528499)

Field	Value
Entity Type	Individual
Organization	Ellen Chirichella
Address	3851 Piper St. U340
City	Anchorage
State	AK
ZIP	99508
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	April 19, 2007

Payer Source	Total Paid
Medicare	$855.8K
Medicaid	$0

Key Findings

Medicare is the sole payer of record for this clinician: lifetime Medicare revenue is $855.8K while Medicaid shows none (no Medicaid billing on file), making this effectively a single‑payer Medicare practice for the data observed. That concentration creates revenue dependence on Medicare reimbursement policy and beneficiary volume in this provider’s service area.

Revenue concentration is highly focused: the precomputed top three Medicare codes account for 74.6% of this provider’s total Medicare revenue, indicating a small number of high‑value oncology therapies dominate earnings. The largest single code, J9271, contributes $434.6K (51.5% of Medicare revenue), so shifts in utilization or reimbursement for these specific drugs would disproportionately affect total revenue.

The provider’s service mix is consistent with outpatient medical oncology and infusion care: J9271 (pembrolizumab) and J0897 (denosumab) are the two largest drug revenue sources, and chemotherapy administration codes such as 96413 and add‑ons like 96417 are also present. In addition, E/M codes 99214 and 99213 appear among top revenue lines, reflecting ongoing office follow‑up and management of established cancer patients alongside in‑office infusion services.

Competitive standing for the principal biologic therapy is modest: J9271 ranks #1102 of 1841 providers (39th percentile) and is characterized in the data as "typical, unremarkable volume for this code," so although J9271 dominates this provider’s revenue mix, the provider is not a national leader in pembrolizumab volume. By contrast, denosumab (J0897) ranks #2184 of 10057 providers (78th percentile) and is also labeled "typical, unremarkable volume for this code," suggesting relatively stronger activity on that supportive‑care agent versus many peers.

Office visit utilization shows above‑median relative activity: 99214 accounts for $76.3K (9.0% of Medicare revenue) and ranks #35988 of 479517 providers (92th percentile), described as "typical, unremarkable volume for this code." This suggests a steady cadence of moderate‑complexity follow‑up visits, consistent with longitudinal management of oncology patients in an outpatient setting.

Ancillary services and monitoring are evident: lab panels and CBCs (80053 and 85025) appear in the top codes and rank in the 92th and 91th percentiles respectively, each labeled "typical, unremarkable volume for this code." Frequent use of these panels aligns with active systemic therapy practice that requires routine laboratory monitoring for treatment safety and toxicity surveillance.

Practice operations include both direct drug administration and transition to home infusion models: G0498 (chemotherapy administration with initiation in clinic and continuation in the community using a portable pump) appears in the top codes, indicating the provider performs infusion starts that may be continued in non‑clinic settings. Presence of pegfilgrastim (J2506) and antiemetic combination therapy (J1454) among revenue drivers further supports a full‑service oncology infusion practice that provides supportive care agents alongside primary anticancer biologics.

Provider tenure is long enough to indicate established practice patterns: the NPI was enumerated on 2007-04-19 (~19 years ago), giving the clinician a sustained presence in the market that corresponds with the observed mix of recurrent office visits, infusion administration, and supportive care billing. That longevity, combined with concentrated Medicare revenue, suggests steady practice operations centered on medically managed oncology care for Medicare beneficiaries.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

45 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	10,600	$40	$434.6K
J0897	Injection, denosumab, 1 mg	6,240	$20	$118.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	600	$130	$76.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	320	$120	$37.7K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	400	$80	$32.5K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	340	$80	$27.8K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	50	$370	$19.9K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	100	$180	$18.3K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	60	$220	$13.8K
G0498	Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community…	60	$160	$9.9K

Showing 1–10 of 45

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 45 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Alaska Distribution

Ellen Chirichella — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Alaska

Full comparison — all codes billed, vs. state median

45 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	9	10	13,300	$40	$609.5K
J0897	9	30	2,700	$20	$82.7K
J2506	3	10	440	$80	$36.8K
96413	6	20	230	$110	$30.2K
J1454	2	10	50	$350	$18.4K
99214	42	1,210	90	$100	$16.2K
99215	84	400	40	$150	$11K
99213	84	1,290	70	$70	$8.5K
G0498	1	10	50	$150	$7.5K
99205	19	140	30	$190	$7.4K

Showing 1–10 of 45

Related Providers

Other providers that share a Tax Identification Number (TIN) with Ellen Chirichella, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Shannon Smiley	AK	Hematology & Oncology Physician	$1.6M	$0
Natalie Wallace	AK	Hematology & Oncology Physician	$1.2M	$0
Theodore Kim	AK	Hematology & Oncology Physician	$1.2M	$0
Katmai Oncology Group, LLC	AK	Medical Oncology Physician	$0	$872.8K
Kendal Webb	AK	Hematology & Oncology Physician	$292.4K	$0
Mary Klix	AK	Hematology & Oncology Physician	$113.4K	$0
Terri Tope	AK	Nurse Practitioner	$48.3K	$0
Charles Buess	AK	Hematology & Oncology Physician	$4.2K	$0

Ellen Chirichella — Billing Profile & Reimbursement Data

Sign up for Ellen Chirichella — Billing Profile & Reimbursement Data policy alerts

Ellen Chirichella — Billing Profile & Reimbursement Data

Sign up for Ellen Chirichella — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Frequently Asked Questions

References